Semaglutide impurity (des-7-Thr-SMT) is a structural derivative that may be produced during the synthesis or degradation of the GLP-1 analog semaglutide. It is characterized by the absence of the threonine residue at position 7. As a drug impurity, its presence may affect the purity, efficacy or safety of semaglutide, so it needs to be strictly monitored and analyzed in drug development and quality control. The detection of this impurity is of great significance to ensure the stability and clinical effect of the diabetes treatment drug semaglutide.
Product Overview
Basic Description |
Structure and function: |
Three-letter sequence |
His-Ala-Glu-Gly-Thr-Phe-Ser-Asp-Val-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly |
Single letter sequence |
HAEGETFSVDVYLGQAAKELIAWLVRGRG |
Molecular formula |
C178H259N45O54S |
Molecular weight |
4,051.9 g/mol |
Product Attributes
purity |
>98% |
form |
Lyophilized powder |
Storage conditions |
Store at -20°C/-80°C away from light |